原发性胆汁性胆管炎预后评分(Mayo、UK-PBC与GLOBE)比较
该研究在国际多中心队列中比较了Mayo风险评分(1989和1994版)、UK-PBC评分和GLOBE评分对熊去氧胆酸治疗的PBC患者预后(肝移植或死亡)的预测价值。共纳入1100例患者,中位随访7.6年,GLOBE评分 discriminatory performance 略优(1年一致性统计量0.80),但各评分间差异无统计学意义,且预测准确性良好。
要点
- GLOBE评分1年一致性统计量0.80,数值上优于UK-PBC和Mayo评分,但差异无统计学意义。
- 所有评分在胆红素>0.6×ULN或FIB-4提示进展期纤维化患者中 discriminative performance 提高。
- Mayo(1989)和GLOBE评分的5年无移植生存预测值与实际值差值分别为+0.4%和+2.5%。
核心结论
- GLOBE、UK-PBC和Mayo风险评分对PBC患者肝移植或死亡的区分能力相当,且预测准确性良好。
研究设计与样本
- 国际多中心队列研究,纳入GLOBAL PBC研究组7个中心中接受熊去氧胆酸治疗的PBC患者1100例。
主要发现
- 中位随访7.6年(IQR 4.1-11.7)期间,42例接受肝移植,127例死亡。
- 1年一致性统计量:MELD为0.68(95%CI 0.64-0.72),UK-PBC为0.74(95%CI 0.67-0.80),Mayo(1989和1994)为0.76(95%CI 0.72-0.81),GLOBE为0.80(95%CI 0.76-0.84)。
- GLOBE评分区分能力数值上最优,但各评分间差异无统计学意义。
- 所有评分在胆红素>0.6×ULN及FIB-4提示进展期纤维化患者中区分能力提高。
- Mayo(1989)和GLOBE评分的预测中位5年无移植生存率与实际值差值分别为+0.4%和+2.5%。
临床怎么用
- 临床可选用任一PBC预后评分(GLOBE、UK-PBC或Mayo)进行风险分层,GLOBE评分数值上略优但差异不显著。
- 对胆红素>0.6×ULN或FIB-4提示进展期纤维化的患者,评分区分能力更佳,可优先用于此类人群的风险评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Comparative data on scores that predict outcome in primary biliary cholangitis (PBC) are scarce. We aimed to assess and compare the prognostic value of the Mayo Risk Score (MRS, 1989 and 1994), UK-PBC score, and GLOBE score in a large international cohort of patients with PBC. METHODS: Ursodeoxycholic acid-treated patients from 7 centers participating in the GLOBAL PBC Study Group were included. The discriminatory performance of the scores was assessed with concordance statistics at yearly intervals up to 5 years. Model for End-stage Liver Disease was included for comparison. Prediction accuracy was assessed by comparing predicted survival and actual survival in Kaplan-Meier analyses. RESULTS: A total of 1,100 ursodeoxycholic acid-treated patients with PBC were included, with a mean (SD) age of 53.6 (12.0) years, of whom 1,003 (91%) were female. During a median follow-up of 7.6 (interquartile range 4.1-11.7) years, 42 patients underwent liver transplantation, and 127 patients died. At 1 year, the concordance statistic for Model for End-stage Liver Disease was 0.68 (95% confidence interval [CI] 0.64-0.72), 0.74 (95% CI 0.67-0.80) for the UK-PBC score, 0.76 (95% CI 0.72-0.81) for the MRS (1989 and 1994), and 0.80 (95% CI 0.76-0.84) for the GLOBE score. The GLOBE score showed superior discriminatory performance, but differences were not statistically different. For all scores, discriminatory performance increased in those with bilirubin >0.6 × ULN and advanced fibrosis estimated with Fibrosis-4. The predicted (median) minus observed 5-year transplant-free survival was +0.4% and +2.5% for the MRS (1989) and GLOBE score, respectively. DISCUSSION: All prognostic scores developed for PBC (GLOBE, UK-PBC, and MRS) demonstrated comparable discriminating performance for liver transplantation or death as well as good prediction accuracy.
引用
- Goet JC, Murillo Perez CF, Harms MH, et al. A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. Am J Gastroenterol. 2021. PMID: 33941746. doi:10.14309/ajg.0000000000001285
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。